Powiadomienia systemowe
- Sesja wygasła!
- Sesja wygasła!
Tytuł artykułu
Treść / Zawartość
Pełne teksty:
Identyfikatory
Warianty tytułu
Języki publikacji
Abstrakty
Targeting apoptosis is an interesting issue in molecular imaging and various modalities have been presented. However, recent experiences in nuclear pharmacy demonstrated the application of small tracer molecules is more desired. This work was conducted for production of a radiolabeled copper complex, i.e. 61Cu-oxinate as a potential PET tracer for apoptosis imaging in oncology. Cu-61 was prepared by natural zinc target irradiation with 22 MeV protons (150 miA) via the natZn(p, xn)61Cu nuclear reaction with a yield of 3.33 mCi/miAh. In order to obtain the best labeling method, optimization reactions were performed for pH, temperature and concentration followed by solid phase extraction. Biodistribution of the tracer was studied in wild-type and fibrosarcoma bearing mice. Under the optimized conditions, radio-thin-layer chromatography (RTLC) and HPLC showed radiochemical purities of 99.99% and 97% respectively (with a minimum specific activity of 16 Ci/mM). Biodistribution of the tracer in fibrosarcoma bearing mice demonstrated a significant tumor uptake after 3 h. Tumor:blood and tumor:muscle ratios were 2.0 and 6.0 after 3 h, respectively.
Słowa kluczowe
Czasopismo
Rocznik
Tom
Strony
175--179
Opis fizyczny
Bibliogr. 15 poz., rys.
Twórcy
autor
autor
autor
autor
autor
autor
autor
- Agricultural, Medical and Industrial Research School (AMIRS-NSTRI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: +98 261 4436397, ajalilian@nrcam.org
Bibliografia
- 1. Daniel KG, Chen D, Yan B, Dou QP (2007) Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer. Front Biosci 12:135–144
- 2. Daniel KG, Gupta P, Harbach RH, Gudia WC, Dou QP (2004) Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 67:1139–1151
- 3. DiGiovanni J, Rymer J, Slaga TJ, Boutwell RK (1982) Anticarcinogenic effects of benzo[e]pyrene and dibenz[a,c]anthracene on skin tumor initiation by polycyclic hydrocarbons. Carcinogenesis 3:371–375
- 4. http://www.generalchem.cn/template/crop/Oxine%20Copper.htm
- 5. Jalilian AR, Mirsadeghi L,Yari-Kamrani Y, Rowshanfarzad P, Kamali-Dehghan M, Sabet M (2007) Development of [64Cu]-DOTA-anti-CD20 for targeted therapy. J Radioanal Nucl Chem 274:563–568
- 6. Jalilian AR, Rowshanfarzad P, Sabet M, Shafiee A (2006) Preparation of [61Cu]-2-acetylpyridine thiosemicarbazone complex as a possible PET tracer for malignancies. Appl Radiat Isot 64:337–341
- 7. Jalilian AR, Sabet M, Rowshanfarzad P, Kamali-Dehghan M, Akhlaghi M, Mirzaii M (2006) Optimization of the production of [61Cu]diacetyl-bis(N4-methylthiosemicarbazone)for PET studies. J Radioanal Nucl Chem 269:147–154
- 8. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ (2001) Tumor uptake of copper-diacetyl-bis(N4--methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 42:655–661
- 9. Ma DF, Lu T, Overstreet DE, Milenic M, Brechbiel W (2002) Novel chelating agents for potential clinical applications of copper. Nucl Med Biol 26:351–358
- 10. McCarthy DW, Bass LA, Cutler PD et al. (1999) High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 26:351–358
- 11. Mahmoud OM, Ford EJ (1983) Absorption and excretion of organic compounds of copper by sheep. J Comp Pathol 551–558
- 12. Monson TP, Henle KJ, Nagle WA, Mansouri A (1991) Tumor-targeted delivery of 8-hydroxyquinoline. Int J Radiat Oncol Biol Phys 20:1263–1271
- 13. Rowshanfarzad P, Jalilian AR, Kyomarsi M et al. (2006) Production, quality control and initial imaging studies of [82mRb]RbCl for PET studies. Nukleonika 51:209–215
- 14. Rowshanfarzad P, Sabet M, Jalilian AR, Kamali-Dehghan M (2006) An overview of copper radionuclides and production of 61Cu by proton irradiation of natZn at a medical cyclotron. Appl Radiat Isot 64:1563–1573
- 15. Thakur ML, Coss R, Howell R et al. (2003) Role of lipid--soluble complexes in targeted tumor therapy. J Nucl Med 44:1293–1300
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-article-BUJ7-0008-0019